Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Pivotal trial for Hunter's syndrome begins dosing

Sep. 25, 2003

Metabolex to finance phase II trials of its insulin sensitizer MBX-102

Sep. 23, 2003

Novel PTP inhibitors in early development at Applied Research Systems

Sep. 22, 2003

Keryx enters first SOAR collaboration for KRX-101

Sep. 22, 2003

Novo Nordisk and Boehringer Ingelheim present new histamine H3 modulators

Sep. 19, 2003

Medtronic acquires remaining rights to rhBMP-2

Sep. 19, 2003

Roche and ParAllele form type 2 diabetes genetic collaboration

Sep. 19, 2003

Phase II program of ISIS-113715 follows encouraging phase I data

Sep. 19, 2003

Cerezyme approved for type 3 Gaucher's disease in E.U.

Sep. 19, 2003

Seasonale receives FDA approval

Sep. 18, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...